Kronox Lab Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 2.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kronox Lab Sciences Limited submitted its audited standalone financial results for Q4 and FY25 along with the auditor's report. Revenue from operations for FY25 stood at Rs 10,019 lakhs, up about 11.5% from Rs 8,986 lakhs in FY24. Profit after tax grew nearly 19.3% to Rs 2,547 lakhs from Rs 2,135 lakhs, with EPS rising to Rs 6.91 from Rs 5.81. For Q4 FY25 alone, revenue was Rs 2,613 lakhs versus Rs 2,218 lakhs in Q4 FY24, while PAT was Rs 632 lakhs. The company is debt-free, operating cash flow jumped to Rs 3,070 lakhs (from Rs 1,742 lakhs), and it paid a dividend of Rs 185 lakhs. Statutory auditor Mahesh Udhwani & Associates issued an unmodified opinion.
This is a routine results filing with clean audit and strong growth in revenue, profit, and cash flow — generally positive for shareholders. Being a recently listed company (IPO June 2024), investors should focus on margin trends and the strong cash generation for future capacity expansion.